SECN-15 / Secarna - LARVOL DELTA

SECN-15: Targeting Neuropilin-1 with antisense oligonucleotides overcomes checkpoint inhibitor resistance in solid tumors (SITC 2025) - "We evaluated the therapeutic potential of NRP1-targeting ASOs in preclinical models, both as monotherapy and in combination with immune checkpoint inhibitors (ICIs).Methods ASOs targeting NRP1 were designed and characterized using our proprietary OligoCreator™ platform...Our preclinical data demonstrate strong anti-tumor efficacy in the monotherapy, as well as the combination therapy setting. Based on these findings, IND-enabling studies and preparations for first-in-human clinical trials are underway."

Checkpoint inhibition • IO biomarker • Breast Cancer • Gastric Cancer • Oncology • Solid Tumor • KDR • NRP1 • TGFBR2

SECN-15: A novel treatment option for patients with checkpoint inhibitor–resistant tumors by targeting Neuropilin-1 with antisense oligonucleotides. (ASCO 2025) - "The recent success of bispecific antibodies targeting PD-1/PD-L1 and VEGF such as ivonescimab has highlighted the potential of combining checkpoint inhibitors with anti-angiogenic approaches... Targeting NRP1 with ASOs is a promising therapeutic strategy for solid cancers. Combining NRP1 ASOs with ICIs significantly enhances anti-tumor efficacy, potentially overcoming current ICI therapy limitations. IND-enabling studies are underway to advance SECN-15 into clinical development."

Checkpoint inhibition • Clinical • IO biomarker • Breast Cancer • Gastric Cancer • Oncology • Solid Tumor • NRP1

Secarna Pharmaceuticals to Present New Data and Clinical Strategy for Lead Antisense Oligonucleotide Program SECN-15 at ASCO 2025 (ACCESSWIRE) - "The new data being presented demonstrate that SECN-15 has a strong safety profile, with sustained systemic NRP1 downregulation, and is well tolerated in both mice and rats, supporting its potential for clinical development. In addition to these safety findings, SECN-15 demonstrates strong single agent and combination efficacy with immune checkpoint inhibitors (ICIs) in tumor models where ICIs have no or limited activity. This is underscored by the functional analysis of SECN-15's mode of action, which shows that SECN-15 leads, among others, to reduction of genes associated with the epithelial-mesenchymal-transition (EMT), a pathway linked to ICI resistance in multiple solid tumor indications."

Preclinical • Solid Tumor

SECN-15: An antisense oligonucleotide-based approach to target expression of Neuropilin-1 induces anti-tumor activity in vivo and boosts efficacy of checkpoint inhibitors Knockdown of Neuropilin-1 via antisense oligonucleotides induces anti-tumor activity in vivo and furthermore improves the efficacy of checkpoint inhibitors (ITOC 2025) - "A robust knockdown of NRP1 was observed in multiple infiltrating cell types, together with increased expression of genes involved in inflammation and decreased expression of genes involved in extracellular matrix organization, which is currently being further analyzed. Preparations to bring the human NRP1-specific ASO 'SECN-15' into the clinic for the treatment of patients with solid cancers are currently underway."

Checkpoint inhibition • IO biomarker • Preclinical • Breast Cancer • Oncology • Pancreatic Cancer • Solid Tumor • NRP1

Human angiotensin converting enzyme 2 specific antisense oligonucleotides reduce infection with SARS-CoV-2 variants. (PubMed, J Allergy Clin Immunol) - "ACE2-targeting ASOs can effectively block SARS-COV-2 infection. Our study provides a new approach for blocking SARS-CoV-2 and other ACE2-targeting virus in high-risk populations."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • ACE2